keyword
MENU ▼
Read by QxMD icon Read
search

Psychopharmacology Review

keyword
https://www.readbyqxmd.com/read/29460163/noradrenergic-targets-for-the-treatment-of-alcohol-use-disorder
#1
REVIEW
Carolina L Haass-Koffler, Robert M Swift, Lorenzo Leggio
The role of norepinephrine (NE) in the development of alcohol use disorder (AUD) has been studied over the past several decades. However, the NE system has been largely ignored for many years as a potential target for medication development for AUD. More recently, preclinical and clinical studies have demonstrated the potential value of targeting NE signaling for developing new pharmacological treatments for AUD. This review contributes to a special issue of Psychopharmacology focused on promising targets for alcohol addiction...
February 20, 2018: Psychopharmacology
https://www.readbyqxmd.com/read/29447060/treatment-of-selective-mutism-based-on-cognitive-behavioural-therapy-psychopharmacology-and-combination-therapy-a-systematic-review
#2
Kasper Rud Østergaard
BACKGROUND: Selective mutism (SM) is a debilitating childhood anxiety disorder characterized by a persistent lack of speech in certain social settings and is considered hard to treat. Cognitive behavioral therapy (CBT) and pharmacological treatments are the best described treatments in the literature. AIM: To test whether there is evidence on treatment based on CBT, medication or a combination of these. METHODS: Systematic and critical review of the literature on CBT and/or pharmacological treatments of SM...
February 15, 2018: Nordic Journal of Psychiatry
https://www.readbyqxmd.com/read/29432246/evaluation-and-management-of-the-child-with-autism-spectrum-disorder
#3
Nicole Baumer, Sarah J Spence
PURPOSE OF REVIEW: Autism spectrum disorder is a neurodevelopmental disorder defined by deficits in social communication and the presence of restricted and repetitive behaviors and interests. This article provides the tools to diagnose and manage patients with autism spectrum disorder. RECENT FINDINGS: Autism spectrum disorder is a heterogeneous condition with varying presentations, multiple etiologies, and a number of comorbidities that impact the course and management of the disorder...
February 2018: Continuum: Lifelong Learning in Neurology
https://www.readbyqxmd.com/read/29429599/behavioral-nutraceuticals-and-diets
#4
REVIEW
Jillian M Orlando
Behavioral problems of companion animals are becoming more widely recognized. As a result, there are a growing number of behavioral nutraceuticals and diets on the market. These products may be useful for the treatment of mild conditions, for clients who are hesitant to give their pet a psychopharmacologic agent, or sometimes in conjunction with psychopharmacologic agents. Veterinarians should critically review the research associated with nutraceuticals and diets, and have an understanding of the functional ingredients and their mechanisms of action before prescribing treatment...
February 8, 2018: Veterinary Clinics of North America. Small Animal Practice
https://www.readbyqxmd.com/read/29415813/advances-in-behavioral-psychopharmacology
#5
REVIEW
Leslie Sinn
Recent studies have led to some groundbreaking findings regarding the use of medications for the support of behavioral health in dogs and cats. Despite tantalizing results, these studies should be viewed in light of their limitations. Consequently, the results of these studies should be applied in the clinical setting with caution and with a full understanding of the potential pros and cons of using these medications. A review of the research available on trazodone, clonidine, detomidine, dexmedetomidine, propranolol, pindolol, maropitant, memantine, venlafaxine, and gabapentin discusses these pros and cons and highlights key points regarding their clinical use and application...
February 5, 2018: Veterinary Clinics of North America. Small Animal Practice
https://www.readbyqxmd.com/read/29403383/how-realistic-are-the-scientific-assumptions-of-the-neuroenhancement-debate-assessing-the-pharmacological-optimism-and-neuroenhancement-prevalence-hypotheses
#6
Stephan Schleim, Boris B Quednow
Since two decades, neuroenhancement is a major topic in neuroethics and still receives much attention in the scholarly literature as well as in public media. In contrast to high hopes at the beginning of the "Decade of the Brain" in the United States and Europe that we subsume under the "pharmacological optimism hypothesis," recent evidence from clinical neuroscience suggests that developing drugs that make healthy people smarter is even more difficult than finding new treatments for patients with mental disorders...
2018: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/29397661/the-present-and-future-of-precision-medicine-in-psychiatry-focus-on-clinical-psychopharmacology-of-antidepressants
#7
REVIEW
Alessandro Serretti
Precision medicine is a concept which is recently gaining momentum in all branches of medicine. In particular in psychiatry it is greatly needed given the huge societal costs of psychiatric disorders and given the long time needed to observe benefit from treatments and the response variability. The future will be based on biological determinants, however until such an interesting but still futuristic aim will be reached, at present we may only rely on clinical features to guide our individualized prescription which is currently still frequently based on personal opinion and subjective previous experiences...
February 28, 2018: Clinical Psychopharmacology and Neuroscience: the Official Scientific Journal of the Korean College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/29392446/psychiatric-aspects-of-acute-porphyria-a-comprehensive-review
#8
REVIEW
Laura Duque-Serrano, Liliana Patarroyo-Rodriguez, Dorothy Gotlib, Juan C Molano-Eslava
PURPOSE OF REVIEW: The aim of this paper is to review psychiatric manifestations, comorbidities, and psychopharmacological management in individuals with acute porphyria (AP). RECENT FINDINGS: Recent literature begins to clarify associations between AP, schizophrenia, bipolar disorder, and other psychopathology. Broad psychiatric symptoms have been associated to acute porphyria (AP) and correspond to a spectrum of heterogeneous manifestations such as anxiety, affective alterations, behavioral changes, personality, and psychotic symptoms...
February 2, 2018: Current Psychiatry Reports
https://www.readbyqxmd.com/read/29389165/an-update-on-experimental-and-clinical-psychopharmacology-something-old-something-new-something-borrowed-something-green
#9
William W Stoops
In this editorial, the author provides an update on Experimental and Clinical Psychopharmacology in several areas. First, the journal will continue to accept original research reports and full reviews as it has in past years. The author hopes to still receive outstanding manuscripts in the journal's primary areas of strength, such as clinical research on alcohol use and cigarette smoking. The journal will also continue to publish an annual special issue on a current topic in the field. Second, the journal now accepts brief communications, brief reviews, and case reports...
February 2018: Experimental and Clinical Psychopharmacology
https://www.readbyqxmd.com/read/29359582/paliperidone-palmitate-three-month-depot-formulation-a-helpful-innovation-with-practical-pitfalls
#10
Judith D Hope, Nicholas A Keks
OBJECTIVE: Paliperidone palmitate is now available as a three-month depot injection. This paper will review the pharmacokinetics, pharmacodynamics, efficacy and tolerability, as well as practical issues and pitfalls for clinicians with this innovative treatment for schizophrenia. CONCLUSION: The three-month depot formulation of paliperidone for the treatment of schizophrenia is not a new compound. The nanocrystalline structure of the three-month formulation is larger and takes longer to disperse than the one-month formulation, hence its extended depot action...
January 1, 2018: Australasian Psychiatry: Bulletin of Royal Australian and New Zealand College of Psychiatrists
https://www.readbyqxmd.com/read/29343873/-un-analisi-bibliometrica-della-produzione-scientifica-sui-farmaci-antipsicotici-atipici-in-italia
#11
Francisco López-Muñoz, Domenico De Berardis, Michele Fornaro, Federica Vellante, Massimo di Giannantonio, Francisco J Povedano-Montero, Maria Póveda Fernández-Martín, Gabriel Rubio, Cecilio Álamo
RIASSUNTO. Introduzione. Lo scopo è stato di condurre uno studio bibliometrico delle pubblicazioni scientifiche peer-reviewed sui farmaci antipsicotici atipici (AAD) in Italia. Metodi. Sono stati selezionati i documenti rilevanti dal database Scopus. Sono stati impiegati diversi indicatori bibliometrici di produzione e dispersione, inclusa la legge di Price sull'aumento delle letteratura scientifica e la legge di Bradford. Sono anche stati calcolati gli indici di partecipazione per quanto concerne i diversi stati...
November 2017: Rivista di Psichiatria
https://www.readbyqxmd.com/read/29337001/antidepressant-treatment-duration-in-pediatric-depressive-and-anxiety-disorders-how-long-is-long-enough
#12
Elizabeth E Hathaway, John T Walkup, Jeffrey R Strawn
Anxiety and depressive disorders are common in the pediatric primary care setting, and respond to both psychotherapeutic and psychopharmacologic treatment. However, there are limited data regarding the optimal treatment duration. This article systematically reviews guidelines and clinical trial data related to antidepressant treatment duration in pediatric patients with depressive and anxiety disorders. The extant literature suggests 9-12 months of antidepressant treatment for youth with major depressive disorder...
January 11, 2018: Current Problems in Pediatric and Adolescent Health Care
https://www.readbyqxmd.com/read/29318515/a-review-of-methods-for-monitoring-adverse-events-in-pediatric-psychopharmacology-clinical-trials
#13
REVIEW
Margaret Coates, Marina Spanos, Pooja Parmar, Tara Chandrasekhar, Linmarie Sikich
Pediatric psychotropic prescription rates are rising, emphasizing the need for careful monitoring of drug safety in this population. Currently, no standardized assessments are used in clinical trials for adverse event (AE) elicitation focused on long-term drug treatment in pediatric patients. Despite a lack of standardized AE elicitation methods in psychiatric clinical trials, it is clear that psychiatric medications have developmentally dependent AEs that differ from those observed in adults. In this review, we discuss the use of general inquiry elicitation, drug-specific checklists, and systematic elicitation scales for AE reporting in pediatric psychopharmacology trials...
January 9, 2018: Drug Safety: An International Journal of Medical Toxicology and Drug Experience
https://www.readbyqxmd.com/read/29259774/advancing-psychosocial-care-in-cancer-patients
#14
REVIEW
Luigi Grassi, David Spiegel, Michelle Riba
Cancer is a devastating disease causing significant psychological problems among patients and their families. In the past few decades, there have been growing implementation and dissemination of screening methods for the psychological consequences of cancer, including distress, depression, anxiety, post-traumatic stress, and demoralisation. Also, guidelines for the management of psychological distress have been developed and endorsed by a number of scientific cancer associations. This review examines some of the most significant related issues, also focusing on recent advances in psychosocial and psychopharmacological interventions as a part of a mandatory, integrated, and comprehensive approach to cancer care...
2017: F1000Research
https://www.readbyqxmd.com/read/29237331/autism-spectrum-disorder-consensus-guidelines-on-assessment-treatment-and-research-from-the-british-association-for-psychopharmacology
#15
Oliver D Howes, Maria Rogdaki, James L Findon, Robert H Wichers, Tony Charman, Bryan H King, Eva Loth, Gráinne M McAlonan, James T McCracken, Jeremy R Parr, Carol Povey, Paramala Santosh, Simon Wallace, Emily Simonoff, Declan G Murphy
An expert review of the aetiology, assessment, and treatment of autism spectrum disorder, and recommendations for diagnosis, management and service provision was coordinated by the British Association for Psychopharmacology, and evidence graded. The aetiology of autism spectrum disorder involves genetic and environmental contributions, and implicates a number of brain systems, in particular the gamma-aminobutyric acid, serotonergic and glutamatergic systems. The presentation of autism spectrum disorder varies widely and co-occurring health problems (in particular epilepsy, sleep disorders, anxiety, depression, attention deficit/hyperactivity disorder and irritability) are common...
January 2018: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/29225554/recent-developments-in-psychopharmaceutical-approaches-to-treating-female-sexual-interest-and-arousal-disorder
#16
REVIEW
Stephanie Both
Purpose of Review: This review summarizes the recent literature and empirical studies on psychopharmacological approaches to treating female sexual interest/arousal disorder (FSIAD). Recent Findings: Several new drugs for FSIAD that are intended to increase sexual responsiveness by influencing central excitatory and inhibitory neuromodulatory processes are under development. Studies on flibanserin resulted in the first approved medication for the treatment of low sexual desire in premenopausal women...
2017: Current Sexual Health Reports
https://www.readbyqxmd.com/read/29215386/improving-the-clinical-pharmacologic-assessment-of-abuse-potential-part-1-regulatory-context-and-risk-management
#17
Edward M Sellers
PURPOSE: This article brings to the attention of drug developers the Food and Drug Administration's (FDA's) recent final Guidance to Industry on Assessment of Abuse Potential and provides practical suggestions about compliance with the Guidance. PROCEDURES: The Guidance areas are reviewed, analyzed, and placed in the context of current scientific knowledge and best practices to mitigate regulatory risk. FINDINGS: The Guidance provides substantial new detail on what needs to be done at all stages of drug development for central nervous system-active drugs...
February 2018: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/29209753/-neuroleptic-malignant-syndrome
#18
REVIEW
R Knorr, J Schöllkopf, E Haen
BACKGROUND: Neuroleptic malignant syndrome (NMS) is a rare but severe undesired complication of psychopharmacological treatment. The mortality has shown a significant decrease since its first description. Knowledge of NMS is important for every clinician because of the need for rapid diagnosis and treatment. OBJECTIVE: This article presents a review and critical appraisal of the current study situation for NMS. Recommendations for diagnostics, differential diagnostics and treatment are presented particularly from a clinical perspective...
December 5, 2017: Der Nervenarzt
https://www.readbyqxmd.com/read/29209235/the-endless-trip-among-the-nps-users-psychopathology-and-psychopharmacology-in-the-hallucinogen-persisting-perception-disorder-a-systematic-review
#19
REVIEW
Laura Orsolini, Gabriele Duccio Papanti, Domenico De Berardis, Amira Guirguis, John Martin Corkery, Fabrizio Schifano
Hallucinogen-persisting perception disorder (HPPD) is a syndrome characterized by prolonged or reoccurring perceptual symptoms, reminiscent of acute hallucinogen effects. HPPD was associated with a broader range of LSD (lysergic acid diethylamide)-like substances, cannabis, methylenedioxymethamphetamine (MDMA), psilocybin, mescaline, and psychostimulants. The recent emergence of novel psychoactive substances (NPS) posed a critical concern regarding the new onset of psychiatric symptoms/syndromes, including cases of HPPD...
2017: Frontiers in Psychiatry
https://www.readbyqxmd.com/read/29194557/caution-is-key-when-prescribing-for-older-adults
#20
Laura G Leahy
The end of the year can trigger the recognition that aging adults are no longer as independent as they once were. Psychiatric nurses and other mental health professionals may see an increase in older adults being referred for treatment. As the most appropriate psychosocial/psychotherapeutic and psychopharmacological treatments are identified for older adults, there are some unique challenges inherent in coordinating the care of this population. It is especially important for prescribing psychiatric advanced practice nurses to update, review, and cross-reference older patients' lists of medications at every appointment...
December 1, 2017: Journal of Psychosocial Nursing and Mental Health Services
keyword
keyword
14627
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"